BCL2 interacting protein 3 pseudogene 16Genealiases: []
Q-omics provides the consensus-scored BNIP3P16 profile across patient tissues and cancer cell-line models. BNIP3P16 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BNIP3P16 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, BNIP3P16 RNA expression shows 13,931 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where BNIP3P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNIP3P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNIP3P16 survival associations across molecular data types. BNIP3P16 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNIP3P16 RNA expression–survival associations across cancer types. High BNIP3P16 expression shows unfavorable associations in ACC, KICH and COAD, but favorable associations in LUAD, OV and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BNIP3P16 RNA expression.
This table summarizes BNIP3P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for BNIP3P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNIP3P16 shows lower tumor expression in KICH and THCA and higher tumor expression in BRCA, LIHC, KIRP and CHOL. The KICH box plot shows higher BNIP3P16 RNA expression in normal versus tumor tissue (log2 FC = −0.389, t-test p < 0.001).
This table shows molecular features associated with BNIP3P16 in patient tissues and cancer cell lines. In patient samples, BNIP3P16 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
